PTHrP analogue (anabolic) Pregnancy: Not indicated for use in females of reproductive potential. There are no human data in pregnant women to inform any drug-associated risks; animal reproduction studies have not been conducted.

Abaloparatide

Brand names: Eladynos

Abaloparatide is a synthetic parathyroid hormone-related protein analogue, an anabolic (bone-forming) agent used to treat osteoporosis in patients at high risk of fracture.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 80 micrograms (80 mcg)

Route: Subcutaneous injection into the periumbilical region of the abdomen. Do not administer intravenously or intramuscularly.

Frequency: Once daily, at approximately the same time every day (rotate the injection site every day)

Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate. Administer the first several doses where the patient can sit or lie down if necessary, in case symptoms of orthostatic hypotension occur. Treatment duration: safety and efficacy have not been evaluated beyond 2 years of treatment; use for more than 2 years during a patient's lifetime is not recommended. Prefilled pen delivers 30 doses of 80 micrograms in 40 microlitres. No UK SPC (eMC) record was retrieved in the bundle — this dose is from US prescribing information (Tymlos) and must be verified against UK labelling.

Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

History of systemic hypersensitivity to abaloparatide or to any component of the product formulation (reactions have included anaphylaxis, dyspnoea and urticaria)

Side effects

Hypercalciuria
Dizziness
Nausea
Headache and palpitations
Fatigue, upper abdominal pain and vertigo (postmenopausal women); in men, injection site erythema/swelling/pain, arthralgia, contusion, diarrhoea, abdominal distension and bone pain

Interactions

No specific drug-drug interaction studies have been performed (US label §7)

Clinical monograph

How it works

It selectively activates the PTH1 receptor in a way that favours bone formation, stimulating osteoblast activity and increasing bone mineral density.

Prescribing in practice

Treatment duration is limited and lifetime cumulative use of anabolic skeletal agents is restricted because of a theoretical osteosarcoma concern observed in animal studies, so prescribing should follow the SPC limits.
It is given by daily subcutaneous injection and can cause orthostatic hypotension and palpitations, particularly after the first doses.
Following a course, sequential antiresorptive therapy is generally needed to maintain the gains in bone density.

Monitoring

Monitor for orthostatic symptoms after injection and check calcium status, with assessment of bone mineral density to guide ongoing osteoporosis management.

Counselling the patient

A daily injection that builds new bone to reduce fracture risk.
Sit or lie down if you feel dizzy or light-headed after an injection, especially at first.
This is a time-limited course, after which another osteoporosis medicine is usually started.

Evidence & guidelines

Abaloparatide reduced vertebral and non-vertebral fractures in the ACTIVE trial, supporting its use as an anabolic osteoporosis therapy as described in the SPC.

Reference: NICE TA991; SmPC Eladynos; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways